Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alexza Pharmaceuticals Inc (NASDAQ:ALXA)

Delayed Data
As of Feb 12
 -0.006 / -1.96%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Other

Company Description

Alexza Pharmaceuticals, Inc. is a pharmaceutical company, which is focused on the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system, or CNS, conditions. The company's product candidates are based on its proprietary technology, the Staccato system. Its lead product candidate is ADASUVE, which is being developed for the acute treatment of agitation in adults with schizophrenia or bipolar disorder. The company's other product candidates, which are in clinical stage includes AZ-007, Staccato nicotine, AZ-10, AZ-002 and AZ-002. It was formerly known as Alexza Molecular Delivery Corp. and changed its name to Alexza Pharmaceuticals, Inc. in July 2005. Alexza Pharmaceuticals was founded by Alejandro C. Zaffaroni on December 19, 2000 and is headquartered in Mountain View, CA.

Contact Information

Alexza Pharmaceuticals, Inc.
2091 Stierlin Court
Mountain View California 94303
P:(650) 944-7000
Investor Relations:



Mutual fund holders8.61%
Individual stakeholders20.36%
Other institutional17.63%

Top Executives

Thomas Braxton KingPresident, Chief Executive Officer & Director
Catherine McAuliffeVice President-Operations
Stacy PalerminiSecretary & Vice President-Finance
Edwin S. KamemotoExecutive Vice President-Research & Quality
Lori H. TakahashiVice President-Pharmaceutical R&D